




Licence Application

Briefing Guide



medical.bwxt.com



ABOUT BWXT MEDICAL LTD.

BWX Technologies, Inc. (BWXT) acquired Sotera Health's Nordion medical isotope business in July 2018, which is now BWXT Medical Ltd. (BWXT Medical).

BWXT Medical is headquartered in Kanata, Ontario and provides its customers, who conduct life-saving medical procedures for patients around the world, the benefit of decades of experience in the development, manufacturing, and delivery of medical isotopes and radiopharmaceuticals.

Since 2018, BWXT Medical has significantly expanded its workforce from approximately 120 to approximately 200 skilled professionals. The company plans to continue to add more local skilled jobs as new and innovative products are developed for the medical industry. Continued growth is backed by BWXT Medical's parent company and both anticipate a long future in the Ottawa community.



WHAT WE DO

BWXT Medical is an experienced manufacturer and supplier of critical medical isotopes and radiopharmaceuticals for research, diagnostic and therapeutic uses. Its customers include radiopharmaceutical companies, hospitals and radiopharmacies. BWXT Medical's Kanata operations produces and supplies the following products:

- Indium In 111 Oxyquinoline: a diagnostic radiopharmaceutical used in the assessment of inflammation and infection.
- TheraSphere™ a sterile, active implantable Class III medical device used to treat liver cancer. BWXT Medical is under contract by Boston Scientific Corporation to supply this product.

Technetium-99m Technology

In 2018, BWXT announced its innovative technology to produce Molybdenum-99 (Mo-99), the parent isotope of Technetium-99m (Tc-99m) which is used in over 40 million diagnostic imaging procedures every year worldwide to diagnose cancer, coronary artery disease and other adverse medical conditions.

Manufactured molybdenum targets from BWXT's facility in Peterborough will be irradiated in a commercial nuclear reactor resulting in the production of Mo-99. The Kanata facility will process the Mo-99 and manufacture Tc-99m generators which will then be transported to hospitals and radiopharmacies across North America.

Pending approval from FDA and Health Canada, BWXT Medical expects to provide a stable, reliable, long-term supply of Tc-99m - supporting the growing demand for diagnostics across the continent for many years to come.

CNSC LICENCE APPLICATION

On December 17, 2018, BWXT Medical submitted an application to the Canadian Nuclear Safety Commission (CNSC) to request issuance of its own Class IB Licence for its facility in Kanata, Ontario. On June 9-10, 2021, the CNSC will hold a public hearing on the application. Since the 2018 acquisition, BWXT Medical employees have been conducting licensed activities in the existing medical isotope facility under Nordion's management and oversight, and under Nordion's Class IB Licence and will continue to do so as we seek our own licence.

BWXT Medical is in full compliance with all regulatory requirements. In the future, BWXT Medical expects to hold its own licence to undertake the nuclear medicine business within the medical isotopes portion of the facility. Upon receipt of its operating licence, BWXT Medical will continue to produce the same types of products previously produced by Nordion reliably for decades in the same facility. BWXT Medical looks forward to expanding its product portfolio to uphold its vision of providing health and hope for patients around the world.

The CNSC regulates the use of nuclear energy and materials to protect health, safety, security and the environment; to implement Canada's international commitments on the peaceful use of nuclear energy; and to disseminate objective scientific, technical and regulatory information to the public¹.

The CNSC considers licence applications for nuclear facilities via a public hearing process that is set out in their Rules of Procedure. The public hearing for a licence application takes into account the views, concerns and opinions of interested parties and intervenors. The hearing will be webcast live on the CNSC's website at nuclearsafety.ca.

KEY DATES:

May 3, 2021 - Public Intervention Submission Deadline

June 9 - 10, 2021 - One-Part Public Hearing (location and time to be determined by the CNSC)

PUBLIC PARTICIPATION IN CNSC HEARINGS

Members of the public, Indigenous groups and stakeholders who have an interest or expertise of information that may be useful to the Commission in reaching its decision, are invited to comment on BWXT Medical's application and can do so by following the CNSC's intervenor process.

Interventions can be made either via a written submission or a written submission accompanied by an oral presentation at the hearing. Requests to intervene must be filed with the Commission Secretariat by May 3, 2021 using the CNSC's online request form or the contact information below:

Senior Tribunal Officer, Secretariat

Tel.: 613-858-7651 or 1-800-668-5284

Fax: 613-995-5086

Email: cnsccinterventions@ccsn.ca

The request to intervene must include the following information:

- A written submission of the comments to be presented to the Commission.
- A statement setting out whether the requester wishes to intervene by way of written submission only or by way of written submission and oral presentation.
- The requester's name, address, telephone number and email address.
- Learn more at <http://www.nuclearsafety.gc.ca/eng/the-commission/hearings/participate/index.cfm>.

¹CNSC website: <http://nuclearsafety.gc.ca/eng/>



RESPONSIBLE AND SAFE OPERATIONS

BWXT Medical operates in one of the most highly regulated industries in the world. Our operation must meet a wide variety of nuclear and health regulatory requirements and we are committed to meeting or exceeding all applicable regulatory requirements.

The safety of our employees, members of the public and the environment is our number one priority.

The CNSC regulates the nuclear energy industry to limit the radiation that employees and members of the public receive. Each year, the public in Canada is exposed to 1.8 mSv of natural background radiation and in 2019, the dose to a member of the public from the Kanata facility was a mere 0.00087 mSv.

OUR IMPACT ON PATIENT HEALTH

BWXT Medical is dedicated to producing diagnostic and therapeutic medical isotopes and radiopharmaceuticals that are relied upon by patients all over the world.

The Indium-111 Oxyquinoline Solution produced at BWXT Medical's Kanata facility helps in the assessment of inflammation and infection, for example diabetic foot.

When patients receive the diagnostic imaging they need, they can begin to seek an effective treatment to improve their health. BWXT Medical's passion to deliver quality nuclear medicine is driven by our commitment to patient health.





M e d i c a l

CONTACT US

BWXT Medical is committed to communicating and engaging with the Kanata community in a timely, transparent and meaningful way. To support this commitment, BWXT Medical has developed a dedicated public information website at: medical.bwxt.com where members of the community can find detailed information about our operations and access the latest news, developments and career opportunities.

Contact us if you have questions, comments or concerns:

BWXT Medical Ltd.

Attention:

Communications & Community Relations

447 March Road


Kanata, Ontario K2K 1X8

Phone: 1.833.657.4565 (toll free)

Email: isotopequestions@bwxt.com

Web: medical.bwxt.com

Join Our Email List: are you interested in staying up-to-date on our operations, licence application and more? Join our email list to receive regular updates. Email us at isotopequestions@bwxt.com or visit our website to subscribe online.



© 2021 BWXT Medical Ltd. All rights reserved.



medical.bwxt.com

People Strong
INNOVATION DRIVEN >